Journey Medical (DERM) Amortizatization of Intangibles (2021 - 2026)
Journey Medical (DERM) posted Amortizatization of Intangibles of $96000.0 for Q1 2026, down 18.64% on a QoQ basis from $118000.0 in Q4 2025, and down 4.95% year-over-year from $101000.0 in Q1 2025.
Journey Medical (DERM) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Journey Medical's Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $96000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles fell 4.95% year-over-year to $96000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $461000.0 (up 33.24% YoY) and the FY2025 annual result came in at $466000.0, up 51.79% from the prior year.
- Amortizatization of Intangibles was $96000.0 for Q1 2026 at Journey Medical, down from $118000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $279000.0 in Q2 2023 and bottomed at $2000.0 in Q4 2023.
- A 5-year average of $75764.7 and a median of $64000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles sank 99.17% — and 2024, when it soared 4600.0%.
- Journey Medical's Amortizatization of Intangibles stood at $16000.0 in 2022, then sank by 87.5% to $2000.0 in 2023, then surged by 4600.0% to $94000.0 in 2024, then increased by 25.53% to $118000.0 in 2025, then retreated by 18.64% to $96000.0 in 2026.
- Business Quant data shows DERM's Amortizatization of Intangibles at $96000.0 in Q1 2026, $118000.0 in Q4 2025, and $123000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Journey Medical | 172.98 Mn | 145.76 Mn | 9.70 Mn | 96,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96,000.00 |
| Mar 31, 2026 | 96,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Sep 30, 2025 | 123,000.00 |
| Sep 30, 2025 | 123,000.00 |
| Jun 30, 2025 | 124,000.00 |
| Jun 30, 2025 | 124,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Dec 31, 2024 | 94,000.00 |
| Dec 31, 2024 | 94,000.00 |
| Sep 30, 2024 | 87,000.00 |
| Sep 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | 62,000.00 |
| Mar 31, 2024 | 62,000.00 |
| Dec 31, 2023 | 2,000.00 |
| Dec 31, 2023 | 2,000.00 |